Market Overview

UPDATE: Jefferies Lowers PT on AbbVie on Attractive Entry Point Potential

Benzinga's Top Initiations
The Market In 5 Minutes: Netflix Dominates, Goldman Sachs Keeps Banks Flowing
Why You (And Another Company) Should Buy Gilead - Dividend Sensei (Seeking Alpha)

In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on AbbVie (NYSE: ABBV), but lowered the price target from $54.00 to $51.00.

In the report, Jefferies noted, “We reiterate Novartis as our Top European and Global Pick with positive growth inflection potential in 2014 and significant restructuring optionality being key drivers. Abbott is our Top US Pick for similar reasons. We highlight Roche, Sanofi and AbbVie as potentially offering particularly attractive entry points following the recent sell-off. AstraZeneca is now our Least Preferred stock.”

AbbVie closed on Thursday at $43.04.

Latest Ratings for ABBV

Oct 2016Leerink SwannInitiates Coverage OnMarket Perform
Sep 2016JP MorganDowngradesOverweightNeutral
Sep 2016Raymond JamesInitiates Coverage onOutperform

View More Analyst Ratings for ABBV
View the Latest Analyst Ratings

Posted-In: Jefferies Jeffrey HolfordAnalyst Color Price Target Analyst Ratings


Related Articles (ABBV)

View Comments and Join the Discussion!